Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

GlaxoSmithKline PLC ADR

Healthcare US GSK

49.72USD
0.72(1.47%)

Last update at 2026-06-03T20:00:00Z

Day Range

49.3949.89
LowHigh

52 Week Range

34.4861.21
LowHigh

Fundamentals

  • Previous Close 49.00
  • Market Cap112050.49M
  • Volume3811598
  • P/E Ratio15.01
  • Dividend Yield3.16%
  • EBITDA11335.00M
  • Revenue TTM32667.00M
  • Revenue Per Share TTM16.13
  • Gross Profit TTM 23720.00M
  • Diluted EPS TTM3.74

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 7238.81M 3477.00M 6064.00M 5628.00M 5442.00M
Minority interest -573.00000M -376.00000M -380.00000M -665.00000M -711.00000M
Net income 5590.74M 2575.00M 4928.00M 4921.00M 4385.00M
Selling general administrative 8989.00M 11015.00M 9385.00M 8372.00M 10975.00M
Selling and marketing expenses - - 371.00M - -
Gross profit 23178.67M 22328.00M 21763.00M 19770.00M 22511.00M
Reconciled depreciation 2314.00M 2551.00M 1527.00M 2298.00M 2524.00M
Ebit 7927.38M 4117.00M 6789.00M 6433.00M 6201.00M
Ebitda 11622.59M 6668.00M 9083.00M 8805.00M 8786.00M
Depreciation and amortization 3695.21M 2551.00M 2294.00M 2372.00M 2585.00M
Non operating income net other - - - - -
Operating income 7011.89M 4021.00M 6745.00M 6433.00M 6201.00M
Other operating expenses 24939.22M 27355.00M 23583.00M 22891.00M 27913.00M
Interest expense 685.64M 657.58M 775.00M 879.00M 784.00M
Tax provision 1112.00M 526.00M 756.00M 707.00M 346.00M
Interest income 531.00M 60.00M 48.00M 76.00M 723.00M
Net interest income -633.00000M -603.00000M -735.00000M -803.00000M -756.00000M
Extraordinary items - 0.00000M 0.00000M 10495.00M 1069.00M
Non recurring - - - - -
Other items - - - - -
Income tax expense 1087.63M 526.00M 756.00M 707.00M 346.00M
Total revenue 31951.12M 31376.00M 30328.00M 29324.00M 34114.00M
Total operating expenses 16166.77M 18307.00M 15018.00M 13337.00M 16310.00M
Cost of revenue 8772.45M 9048.00M 8565.00M 9554.00M 11603.00M
Total other income expense net 226.92M -544.00000M -681.00000M -805.00000M -759.00000M
Discontinued operations - - - 10495.00M 1069.00M
Net income from continuing ops 6289.00M 2951.00M 6535.00M 4921.00M 5096.00M
Net income applicable to common shares 5716.00M 2575.00M 4928.00M 14956.00M 4385.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 61010.57M 59463.00M 75219.57M 60146.00M 79103.00M
Intangible assets 16718.56M 15515.00M 18826.25M 14318.00M 30079.00M
Earning assets - - - - -
Other current assets 420.26M 1615.00M 715.16M 7746.00M 8756.00M
Total liab 45015.74M 46377.00M 58908.51M 50050.00M 57761.00M
Total stockholder equity 16348.21M 13671.00M 17014.76M 10598.00M 15055.00M
Deferred long term liab - - - - -
Other current liab 2992.73M 15183.00M 17750.04M 2595.00M 958.00M
Common stock 1346.63M 1348.00M 1718.43M 1347.00M 1347.00M
Capital stock 1349.00M 1348.00M 1348.00M 1347.00M 1347.00M
Retained earnings 10191.06M 7796.00M 9228.28M 4363.00M 7944.00M
Other liab - - - 10205.00M 13519.00M
Good will 7005.66M 6982.00M 8682.66M 7046.00M 10552.00M
Other assets 7635.00M 7656.00M 6683.00M 6852.00M 6894.00M
Cash 3391.03M 3693.00M 3742.81M 3723.00M 4274.00M
Cash and equivalents 2389.00M 2750.00M 1998.00M 3723.00M -
Total current liabilities 21353.40M 21697.00M 26857.49M 22810.00M 23670.00M
Current deferred revenue - - 283.01M - 1557.00M
Net debt 14297.83M 13293.00M 19226.53M 17264.00M 19899.00M
Short term debt 3006.71M 2349.00M 3586.01M 3952.00M 3601.00M
Short long term debt 2875.00M 2181.00M 2657.00M 3785.00M 3398.00M
Short long term debt total 17688.85M 16986.00M 22969.35M 20987.00M 24173.00M
Other stockholder equity 4810.53M 4527.00M 4032.19M 4888.00M 5764.00M
Property plant equipment 10048.00M 10073.00M 9957.00M 9620.00M 10672.00M
Total current assets 17479.22M 16997.00M 23767.37M 20769.00M 18674.00M
Long term investments - - - - -
Net tangible assets - - - -10766.00000M -25576.00000M
Short term investments 8.98M 21.00M 2863.20M 4154.00M 61.00M
Net receivables 7745.36M 5999.00M 9437.34M 7053.00M -200.00000M
Long term debt 14015.00M 13703.00M 14154.00M 17035.00M 20572.00M
Inventory 5913.59M 5669.00M 7008.85M 5146.00M 5783.00M
Accounts payable 15353.97M 3462.00M 4738.43M 16263.00M 17554.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - -552.00000M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 2035.86M - -
Additional paid in capital - - 3451.00M - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - -3447.00000M - -
Accumulated amortization - - - - -
Non currrent assets other 2144.22M 1928.00M 808.22M 5348.00M 1755.00M
Deferred long term asset charges - - - - -
Non current assets total 43531.35M 42466.00M 51452.20M 39377.00M 60429.00M
Capital lease obligations 830.00M 1102.00M 1207.00M 1008.00M 1015.00M
Long term debt total 14708.00M 14637.00M 15205.00M 17035.00M 20572.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 11.00M -1229.00000M -1595.00000M -8772.00000M 334.00M
Change to liabilities - - - 494.00M 284.00M
Total cashflows from investing activities -5722.77789M -1229.00000M -2404.06226M -8772.00000M -1777.00000M
Net borrowings 1506.00M -1166.00000M -2370.00000M -4824.00000M -2210.00000M
Total cash from financing activities -1593.30117M -4726.00000M -6068.57909M 823.00M -7589.00000M
Change to operating activities - - - -1425.00000M 1260.00M
Net income 5590.74M 2951.00M 6125.76M 4921.00M 5096.00M
Change in cash -206.06306M 545.00M -735.58390M -394.00000M -1443.00000M
Begin period cash flow 3597.09M 2858.00M 4478.40M 3819.00M 5262.00M
End period cash flow 3391.03M 3403.00M 3742.81M 3425.00M 3819.00M
Total cash from operating activities 7142.96M 6554.00M 7890.89M 7403.00M 7952.00M
Issuance of capital stock 15.00M 20.00M 10.00M 25.00M 21.00M
Depreciation 3695.21M 2551.00M 2851.56M 2298.00M 2524.00M
Other cashflows from investing activities 1459.30M -1219.00000M 14.92M -6514.00000M 36.00M
Dividends paid 2507.81M 2444.00M 2793.14M -3467.00000M -3999.00000M
Change to inventory -140.00000M -294.00000M -527.05398M -269.00000M 25.00M
Change to account receivables - 340.00M -806.74064M -158.00000M -782.00000M
Sale purchase of stock -1362.00000M 20.00M -197.00000M 25.00M -1643.00000M
Other cashflows from financing activities -573.15806M -1136.00000M -341.83926M 8887.00M 27.00M
Change to netincome - - - -8342.00000M 105.00M
Capital expenditures 1318.46M 2982.00M 1633.37M 2258.00M 2931.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -608.36914M 2090.00M -1064.05238M 271.00M -473.00000M
Stock based compensation 374.00M 344.00M 307.00M 346.00M 367.00M
Other non cash items -1534.61605M -1382.00000M 1052.86M -433.00000M 756.00M
Free cash flow 5824.50M 3572.00M 6257.52M 5145.00M 5021.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GSK
GlaxoSmithKline PLC ADR		 0.72 1.47% 49.72 15.01 22.22 3.43 5.17 3.07 9.63
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

GlaxoSmithKline PLC ADR

79 New Oxford Street, London, United Kingdom, WC1A 1DG

Key Executives

Name Title Year Born
Ms. Emma Natasha Walmsley CEO & Director 1970
Mr. Iain James Mackay CFO & Exec. Director 1962
Ms. Julie Brown Chief Financial Officer 1962
Ms. Shobie Ramakrishnan Chief Digital & Technology Officer NA
Mr. Tony Wood Chief Scientific Officer NA
Ms. Sarah Elton-Farr Head of Investor Relations NA
Mr. James Ford Sr. VP & Group Gen. Counsel of Legal & Compliance NA
Ms. Sally Jackson Sr. VP of Global Communications & CEO Office NA
Ms. Diana Conrad Chief People Officer NA
Mr. David Simon Redfern Chief Strategy Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions